uniQure (NASDAQ:QURE) Shares Gap Up Following Analyst Upgrade

uniQure N.V. (NASDAQ:QURE) gapped up prior to trading on Monday after Royal Bank Of Canada upgraded the stock from a sector perform rating to an outperform rating. The stock had previously closed at $14.27, but opened at $18.02. Royal Bank Of Canada now has a $35.00 price target on the stock, up from their previous price target of $11.00. uniQure shares last traded at $16.1640, with a volume of 5,988,132 shares changing hands.

A number of other brokerages have also recently weighed in on QURE. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Tuesday, February 10th. Mizuho restated a “neutral” rating and set a $12.00 price target (down from $33.00) on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $15.00 to $60.00 in a research report on Monday. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $40.08.

Insider Activity

In other uniQure news, insider Jeannette Potts sold 3,412 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares in the company, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is currently owned by company insiders.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Wells Fargo upgraded uniQure from Equal Weight to Overweight and raised its price target to $60, signaling strong upside expectations from one large shop. Read More.
• Positive Sentiment: Royal Bank of Canada upgraded uniQure from Sector Perform to Outperform with a $35 price target — another sizable upward re‑rating that supports the rally.
• Positive Sentiment: Market reaction tied to the exit of a senior FDA/CBER official (reported as a catalyst); investors interpret the departure as reducing near‑term regulatory risk around the AMT‑130 Huntington’s program. Read More.
• Neutral Sentiment: News roundups explain the surge and market reaction but add little new data — useful for context but not a driver by itself. Read More.
• Neutral Sentiment: Broader market weakness in futures could cap upside or increase intraday volatility for biotech names including QURE. Read More.
• Negative Sentiment: Regulatory dispute around AMT‑130 remains unresolved and media coverage describes growing confusion and public rebukes — this raises the chance of additional trials/delays that could materially damage the therapy’s timeline and valuation. Read More.
• Negative Sentiment: Several law firms have filed or solicited class‑action claims and are reminding shareholders of a lead‑plaintiff deadline (April 13, 2026), introducing legal risk and potential management distraction. Read More.
• Negative Sentiment: Insider selling (disclosed early March) and prior analyst cuts/negative coverage remain a headwind and could limit sustained upside absent clear regulatory progress. Read More.
• Negative Sentiment: Earlier public criticism from FDA officials characterizing the Huntington’s program as unsuccessful underpins the regulatory risk that sparked the prior selloff; that risk has not been fully resolved. Read More.

Institutional Investors Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the company. Private Trust Co. NA acquired a new stake in shares of uniQure in the 3rd quarter valued at approximately $28,000. Torren Management LLC acquired a new position in shares of uniQure during the 4th quarter worth $28,000. Jones Financial Companies Lllp increased its holdings in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. IFP Advisors Inc purchased a new position in uniQure during the 4th quarter valued at about $48,000. Finally, Smartleaf Asset Management LLC acquired a new position in uniQure during the fourth quarter worth about $48,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Trading Up 14.3%

The company has a market cap of $1.02 billion, a price-to-earnings ratio of -4.73 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The business’s 50-day simple moving average is $22.04 and its 200-day simple moving average is $29.63.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.